FCGR2A and breast carcinoma: Several studies concerning FCGR polymorphisms and efficacy of trantuumab and rituximab demonstrated that FCGR2A H131R and FCGR3A V158F could predict clinical efficacy and survival of patients with breast cancer and lymphoma, respectively [17, 38].